Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,965 total articles

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Aug 24, 2026
Derek Hwang
Press Releases

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc Ltd.'s subsidiary NeuroThera Labs, in collaboration with Clearmind Medicine, has advanced their psychedelic drug pipeline with a newly published U.S. patent application covering a novel combination of MDMA and N-acylethanolamines (such as PEA) for the treatment of PTSD, anxiety, and eating disorders. This patent publication coincides with …

SPRC
Callan JMB Retains Northern Oil and Gas Founder Michael Reger as President of Callan Power; Northern Oil and Gas Now Valued at Approximately $2.9 Billion
Aug 24, 2026
Nina Shah
Press Releases

Callan JMB Retains Northern Oil and Gas Founder Michael Reger as President of Callan Power; Northern Oil and Gas Now Valued at Approximately $2.9 Billion

Callan JMB Inc. has appointed Michael Reger, founder and former CEO of Northern Oil and Gas, as President of its new subsidiary Callan Power LLC, focused on oil and gas resource development, energy resilience, and domestic manufacturing of critical electrical equipment. Leveraging Reger's extensive energy industry and public company leadership expe…

CJMB
EVA LIVE EXPANDS INTO GLOBAL GAMING MARKET PROJECTED TO EXCEED $200 BILLION THROUGH MAJORITY OWNERSHIP OF INTERNATIONAL GAMING ALLIANCE
Aug 24, 2026
Priya Menon
Press Releases

EVA LIVE EXPANDS INTO GLOBAL GAMING MARKET PROJECTED TO EXCEED $200 BILLION THROUGH MAJORITY OWNERSHIP OF INTERNATIONAL GAMING ALLIANCE

Eva Live Inc. announces its 60% majority ownership of International Gaming Alliance (IGA), marking its strategic expansion into the global online gaming and lottery market. IGA has signed a three-year Master Services Agreement with Lottery.com International, enabling operations across multiple international territories. Eva Live will leverage its A…

GOAI
Expion Announces $9.0 Million Initial Closing of Private Placement
Aug 24, 2026
Maya Rios
Press Releases

Expion Announces $9.0 Million Initial Closing of Private Placement

Expion Energy, Inc. announced the closing of a $9 million initial tranche of a private placement offering involving 8% Convertible Debentures and Warrants, with potential to raise an additional $91 million. The proceeds will be used to acquire oil and gas assets in Eastern Louisiana and for general corporate expenses. The company is broadening its …

XPON
La Rosa Holdings Corp. Reports First Half 2026 Results Highlighted by 10% Gross Profit Growth and 42% Improvement in Operating Loss
Aug 24, 2026
Jordan Park
Press Releases

La Rosa Holdings Corp. Reports First Half 2026 Results Highlighted by 10% Gross Profit Growth and 42% Improvement in Operating Loss

La Rosa Holdings Corp., a US-based real estate and PropTech company, announced first half 2026 financial results marked by a nearly 10% increase in gross profit to $3.7 million and a 42% reduction in operating loss to $4.2 million compared to the prior year. The company also reported a 25% decrease in operating expenses and a 9.4% improvement in ne…

LRHC
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Aug 24, 2026
Nina Shah
Press Releases

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals has earned its third $10 million milestone payment in 2026 from Novo Nordisk following successful patient dosing in the Phase 1 trial of LX9851, a novel oral small molecule for obesity and metabolic disorders. This achievement brings total milestone payments to $75 million out of a potential $1 billion collaboration deal. Th…

LXRX
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
Aug 24, 2026
Leila Farooq
Press Releases

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia, a leader in cellular therapeutics for cardiovascular diseases, announced FDA confirmation of Pre-Submission Meeting minutes for its Helix Transendocardial Delivery Catheter. This ratification supports BioCardia's planned follow-on pre-submission intended to enable Helix's approval via the De Novo regulatory pathway, potentially accelerat…

BCDA
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Aug 24, 2026
Ajmal Hussain
Press Releases

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Amarin Corporation plc announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026 featuring new analyses from the REDUCE-IT trial and mechanistic EPA data. These presentations cover treatment adherence, long-term outcomes, and biomarker insights related to cardiovascular risk reduction with icosapent ethyl (VASCEPA/V…

AMRN
Edible Garden and Square Roots Announce Strategic Partnership to Accelerate Farm-to-Formula® Functional Nutrition Platform
Aug 24, 2026
Marcus Reed
Press Releases

Edible Garden and Square Roots Announce Strategic Partnership to Accelerate Farm-to-Formula® Functional Nutrition Platform

Edible Garden AG, a Nasdaq-listed leader in controlled environment agriculture, announced a strategic partnership with Square Roots to develop a new generation of clean-label, functional ready-to-drink beverages. Combining Square Roots' expertise in plant science with Edible Garden's advanced Farm-to-Formula® platform and aseptic manufacturing, the…

EDBL
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
Aug 24, 2026
Caleb Monroe
Press Releases

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

Biogen and Eisai announced US availability of LEQEMBI IQLIK®, a subcutaneous autoinjector for initiation and maintenance therapy of early Alzheimer's disease, offering a more convenient and flexible alternative to intravenous infusion. The treatment, supported by robust clinical trial data demonstrating slowed disease progression and significant co…

BIIB
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Aug 24, 2026
Priya Menon
Press Releases

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Clearmind Medicine Inc., a clinical-stage biotech focused on psychedelic-derived neuroplastogens, announced the U.S. publication of a patent application covering a novel combination of MDMA and N-acylethanolamines such as PEA, aimed at treating PTSD, anxiety, and eating disorders. This comes alongside the FDA's newly finalized guidance for clinical…

CMND
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Aug 24, 2026
Ajmal Hussain
Press Releases

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare has approved IMCIVREE® (setmelanotide) to treat patients with acquired hypothalamic obesity (HO), a rare disease characterized by significant weight gain due to hypothalamic injury. Supported by positive Phase 3 trial data, this marks IMCIVREE as the first approved…

RYTM
Evolution Metals & Technologies Corp. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes
Aug 24, 2026
Ajmal Hussain
Press Releases

Evolution Metals & Technologies Corp. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes

Evolution Metals & Technologies Corp. (Nasdaq: EMAT), a U.S.-based critical materials and manufacturing company, announced its preliminary inclusion in FTSE Russell's Russell 3000® and Russell 2000® indexes, effective September 21, 2026, pending final review. This inclusion is anticipated to increase the company's visibility among institutional and…

EMAT
ASML reports transactions under its current share buyback program
Aug 24, 2026
Priya Menon
Press Releases

ASML reports transactions under its current share buyback program

ASML Holding N.V., a global leader in semiconductor equipment manufacturing, has disclosed recent transactions under its ongoing share buyback program announced in January 2026. Over five consecutive days in August, ASML repurchased a total of approximately 252,684 shares at weighted average prices ranging from €1,506.98 to €1,618.13 per share. The…

ASML
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Aug 24, 2026
Avery Klein
Press Releases

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

Humacyte, Inc. announced that following favorable discussions with the FDA, it intends to file a supplemental Biologics License Application (BLA) in November 2026 to expand approval of its acellular tissue engineered vessel (ATEV) for dialysis access. This follows FDA approval of ATEV for vascular trauma in 2024. The application will be supported b…

HUMA
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
Aug 24, 2026
Jordan Park
Press Releases

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Biopharma, listed on NYSE American as AEON, has named Paul Lee, M.D., Ph.D., former Deputy Director at the FDA's Office of Neuroscience, as acting Chief Regulatory Officer. Dr. Lee, who has been advising AEON on regulatory strategy via Clintrex Research LLC, will now lead the company’s interactions with the FDA and oversee the regulatory roadm…

AEON